2Q led by currency and HCQS, approvals remain key ff Launches in niche therapies such as transdermals (expect 2 in FY17E), vaccines (expect few launches by FY17E in India), derma products commercialization over next 3 years (facility yet to be inspected by the USFDA) and a potential biologics...